Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SHR0302 (ARQ252) is a JAK inhibitor that binds JAK1 with stronger affinity than others (Selectivity for JAK1 is more than 10 times for JAK2, 77 times for JAK3, 420 times for Tyk2).
説明 | SHR0302 (ARQ252) is a JAK inhibitor that binds JAK1 with stronger affinity than others (Selectivity for JAK1 is more than 10 times for JAK2, 77 times for JAK3, 420 times for Tyk2). |
In vitro | SHR0302 (1nM-10μM) exerted an inhibitory effect on the activation, proliferation and migration of hepatic stellate cells (HSCs). SHR0302 induced the apoptosis of HSCs. The pharmacological inhibition of the JAK1/signal transducer and activator of transcription (STAT)3 pathway led to the disruption of functions essential for HSC[1]. |
In vivo | SHR0302 may attenuate the severity of AA rats, partially through reducing Th17 function and total B cell proportion by inhibiting JAK1-STAT3 phosphorylation[2]. |
別名 | ARQ252 |
分子量 | 414.48 |
分子式 | C18H22N8O2S |
CAS No. | 1445987-21-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30 mg/mL(72.38 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SHR0302 1445987-21-2 Angiogenesis Apoptosis Chromatin/Epigenetic JAK/STAT signaling Stem Cells JAK Th17 B-cell Inhibitor inhibit arthritis collagen migration hepatic ARQ 252 JAK1 phosphorylation anti-proliferation ARQ252 ARQ-252 JAK1-STAT3 SHR 0302 fibrosis SHR-0302 anti-inflammatory Janus kinase inhibitor